Sangamo Therapeutics Inc
SGMO
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.66M
Close$
$2.35
3072% upside
Current Fair Value
3072% upsideUndervalued by 3072% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $30.66 Million |
|---|---|
| Enterprise Value | $28.30 Million |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $-0.44 |
| Beta | 1.3 |
| Outstanding Shares | 389,616,000 |
Return
| Return on Equity | 650.65% |
|---|---|
| Return on Assets | -205.67% |
| Return on Invested Capital | -1839.57% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | -0.07 |
| Enterprise Value to Revenue | 0.82 |
| Enterprise Value to EBIT | -0.23 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.89 |
| Debt to Equity | -1.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$20.65 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$14.67 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6966▼ 30.60% |
|---|---|
| Total Calls | 1,069,800▲ 31.44% |
| Total Puts | 745,200▼ 8.68% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 31.20%▲ 10.74% |
|---|---|
| Total Invested | $26.03M▼ 0.48% |
| Investors Holding | 118▲ 7.00% |
ESG Score
No data
About Sangamo Therapeutics Inc
CEO: Alexander Macrae